title: [A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
abstract: A 57-year-old woman suffering from lower abdominal malaise was diagnosed with cStage IV advanced gastric cancer because of simultaneous liver metastasis and peritoneal dissemination. Because she was regarded as inoperable, she was administered combined immunochemotherapy comprising S-1/paclitaxel(PTX) and Krestin(PSK). One course of therapy lasted for 3 weeks as follows: 80 mg/m2 of S-1 on days 1-14 orally, 50 mg/m2 of PTX on days 1 and 8 intravenously, and 3g/day of PSK on days 1-21 orally. After 20 courses of this treatment, the metastatic liver tumor and peritoneal dissemination had disappeared on the abdominal computed tomography scan. At that time, curative resection was considered possible and she underwent total gastrectomy (Roux-en Y) with D2 lymphadenectomy. Histopathological examination revealed pStage IB [pT2 (mp), pN0] and the histological effects of the main tumor were diagnosed as grade 2. She is alive and free from recurrent disease for more than 6 years, and remains in a good condition. This combination of immunochemotherapy using S-1/PTX/PSK can be safe and effective, and is an initial treatment option for unresectable advanced gastric cancer.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: Kazuya
authors.initials: K
authors.lastname: Muguruma
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Sakurai
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagahara
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Amano
authors.forename: Eiji
authors.initials: E
authors.lastname: Noda
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kubo
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Maeda
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Sawada
authors.forename: Masaichi
authors.initials: M
authors.lastname: Ohira
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy; D011509:Proteoglycans / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D011509:Proteoglycans; C079198:S 1 (combination); D005641:Tegafur; C010770:polysaccharide-K; D010094:Oxonic Acid; D017239:Paclitaxel